Companies say their joint drug extends life of cancer patients by one-third

04/27/2004 | MarketWatch

Three pharmaceutical manufacturers who joined in a venture to create the cancer-relief pill, Tarceva, say their trials show the drug extends the life of cancer patients by as much as one-third and they are looking for FDA approval by early next year. The study of the drug is to be presented in June, but OSI Pharmaceuticals, Genentech and Roche Holdings released preliminary results of the trial they said prove the greater effectiveness of their product.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC